Tag: Cancer

WASHINGTON, D.C., May 13, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) has announced that the Janssen Pharmaceutical Companies of Johnson & Johnson will be the recipient of the ...

PRESS RELEASE: 13 May 2022, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 13 May 2022 Mechelen, Belgium, 13 May 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an ...

New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people ...

Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 millionMyovant also eligible to receive tiered royalties from the ...

MUMBAI, India, May 9, 2022 /PRNewswire/ -- Datar Cancer Genetics ("Datar"), a world-leading cancer research corporation today announced a $250 million contract with Artemis DNA, a leading USA-based diagnostic laboratory company ...

MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, ...

Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU to earlier use in metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or ...

Three therapeutic leads have been identified for the Company’s Immuno-Oncology program Resulting in an accelerated timeline for the program, progressing to preclinical assessment in 2022, approx. 12 months earlier than ...

PRESS RELEASE: 4 May 2022, 07:00 CEST New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine ...

Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® ...